Xth Eurasian Hematology-Oncology Congress

http://www.ehog.net/

 

Ph-like ALL Should Be Treated as the Other B ALL After Demonstration of the Right Target and Best Trial / Registry Context

19 views
December 13, 2019
Comments 0
Login to view comments. Click here to Login